Within 30 months, Insilico Medicine’s ISM001-055, an AI-engineered inhibitor aimed against Traf2- and Nck-interacting kinase (TNIK) for idiopathic pulmonary fibrosis, progressed from concept to phase I trials, demonstrating the efficacy of AI in pharmaceutical development [199,200]. This evidence concerns the gene TNIK and pulmonary fibrosis.